Biropepimut-S in phase IIb head and neck cancer trial
Biropepimut-S (GL-0817) is a highly engineered peptide immunomodulator currently in a 45-site, seven country clinical trial to prevent recurrence of high risk squamous cell cancer of the oral cavity.
Biropepimut-S is targeted against important epitopes within the cancer protein MAGE-A3. MAGE-A3 is expressed in some cases of head and neck cancer, multiple myeloma, lung cancer and many other tumor types. Designed in response to previous challenges with clinical immunomodulator studies, biropepimut-S has a number of advanced features that are not available in any competitive product.